BLAINTRAMUSCULAR, SUBCUTANEOUSINJECTABLE
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
DAXXIFY (botulinum toxin type a) by Cerevance is acetylcholine release inhibitors [moa]. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAXXIFY is a botulinum toxin type A formulation approved by the FDA in September 2022 for intramuscular and subcutaneous injection. It works by inhibiting acetylcholine release at the neuromuscular junction, paralyzing targeted muscles. The product is positioned in the peak lifecycle stage, indicating mature market penetration in aesthetic and therapeutic indications.
Peak
At peak lifecycle, DAXXIFY likely supports a stable, mature commercial team focused on market maintenance and competitive defense rather than rapid growth expansion.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)
Started Sep 2024
50 enrolled
Traumatic Brain Injury
A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants
Started Oct 2023
249 enrolled
Masseter Muscle Prominence
Botulinum Toxin Type A for Cold Intolerance Secondary to Digital Amputations and Replantations: A Pilot Study
Started Jun 2021
28 enrolled
Cold Intolerance
Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease
Started Jan 2021
40 enrolled
Dystonia DisorderParkinson Disease
CLINICAL EFFECT OF BOTULINUM TOXIN TYPE A IN TREATMENT OF SPASTICITY
Started Mar 2019
70 enrolled
SpasticityBrain InjuriesSpinal Cord Injuries+1 more
Worked on DAXXIFY at Cerevance? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.